Skip to content

Study · Non-randomized trial · n = 7 · 2009

7 results

Successful use of weekly pegvisomant administration in patients with acromegaly.

Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ

European journal of endocrinology1 May 2009Cited by 25 (Europe PMC)

PMID19411301 (opens in a new tab)DOI10.1530/eje-08-0990 (opens in a new tab)PepBankPUB-19411301
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In acromegaly patients receiving less frequent pegvisomant, headaches led to two withdrawals at 0+24 weeks.

    In plain wordsIn acromegaly patients receiving less frequent pegvisomant, headaches led to two withdrawals.

    Peptide
    Pegvisomant
    Outcome
    Not applicableHeadache-related withdrawals
    Study

    n = 7

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Withdrawals
    2 patients
    reported result

    Source sentences

    Summary
    Headaches led to two patient withdrawals at 0+24 weeks.
    1 context sentence
    Summary · context
    A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, IGF1 remained stable and within age-adjusted reference ranges with twice-weekly pegvisomant (baseline 145+/-39 versus 124+/-39 ng/ml).

    In plain wordsIn acromegaly patients, IGF1 remained stable with twice-weekly pegvisomant compared with daily dosing at baseline.

    Peptide
    Pegvisomant
    Outcome
    No significant changeIGF1 with twice-weekly dosing
    Study

    n: not reported in source

    Comparator
    Daily dosing baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    IGF1
    145 ng/ml
    baseline
    IGF1
    124 ng/ml
    twice-weekly

    Source sentences

    Summary
    Mean pre-dose serum IGF1 levels remained stable with the different administration regimens (IGF1 baseline 145+/-39 ng/ml, twice-weekly 124+/-39 ng/ml and once-weekly 127+/-22 ng/ml) and all values were within age adjusted IGF1 reference range.
    1 context sentence
    Summary · context
    A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration.
  3. 03HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, IGF1 remained stable and within age-adjusted reference ranges with once-weekly pegvisomant (baseline 145+/-39 versus 127+/-22 ng/ml).

    In plain wordsIn acromegaly patients, IGF1 remained stable with once-weekly pegvisomant compared with daily dosing at baseline.

    Peptide
    Pegvisomant
    Outcome
    No significant changeIGF1 with once-weekly dosing
    Study

    n: not reported in source

    Comparator
    Daily dosing baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    IGF1
    145 ng/ml
    baseline
    IGF1
    127 ng/ml
    once-weekly

    Source sentences

    Summary
    Mean pre-dose serum IGF1 levels remained stable with the different administration regimens (IGF1 baseline 145+/-39 ng/ml, twice-weekly 124+/-39 ng/ml and once-weekly 127+/-22 ng/ml) and all values were within age adjusted IGF1 reference range.
    1 context sentence
    Summary · context
    A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly patients converted to twice-weekly then once-weekly pegvisomant, the dose was reduced in two patients.

    In plain wordsIn acromegaly patients switched to weekly pegvisomant dosing, two had their dose reduced.

    Peptide
    Pegvisomant
    Outcome
    Not applicableDose reductions
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Dose reductions
    2 patients
    reported result

    Source sentences

    Summary
    PegV dose was reduced in two patients and five opted to continue weekly administration at trial termination.
    1 context sentence
    Summary · context
    A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration.
  5. 05HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, five chose to continue weekly pegvisomant at trial termination.

    In plain wordsIn acromegaly patients, five chose to continue weekly pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    Not applicableContinued weekly administration
    Study

    n: not reported in source

    Outcome group
    Treatment continuation · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Continued weekly treatment
    5 patients
    reported result

    Source sentences

    Summary
    PegV dose was reduced in two patients and five opted to continue weekly administration at trial termination.
    1 context sentence
    Summary · context
    A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration.
  6. 06HumanNon-randomized trialSafety outcome

    In acromegaly patients, safety parameters remained stable during less frequent pegvisomant dosing.

    In plain wordsIn acromegaly patients, safety measures remained stable during less frequent pegvisomant dosing.

    Peptide
    Pegvisomant
    Outcome
    No significant changeSafety parameters
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Safety and quality of life parameters remained stable.
    1 context sentence
    Summary · context
    A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration.
  7. 07HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, quality of life remained stable during less frequent pegvisomant dosing.

    In plain wordsIn acromegaly patients, quality of life remained stable during less frequent pegvisomant dosing.

    Peptide
    Pegvisomant
    Outcome
    No significant changeQuality of life
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Safety and quality of life parameters remained stable.
    1 context sentence
    Summary · context
    A two center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegV (median dose 15 mg daily (range 10-20 mg od), IGF1 normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.